The H7N9 candidate vaccine strains virus (CCVs) (NIBRG-268) was obtained from the NIBSC. This virus contains six internal genes from the egg-adapted high-growth A/PR8 virus and two surface protein genes (HA and NA) from A/Anhui/1/2013 (H7N9). This strain was further adapted to MDCK cells (ATCC CCL-34), which were purchased from the Food Industry Research and Development Institute, Hsinchu, Taiwan. The influenza strain H7N9 were originally derived from the egg process. The egg-derived CCVs do not grow well in MDCK cell culture. The re-adapted process was done by choosing better replication colonies in the plaque assay. Generally, the process needs to be repeated 3 to 10 times before obtaining the high growth CVVs in the MDCK cell culture. For preparation of the vaccine standard antigen, OptiPro serum-free medium (Invitrogen) was used for MDCK cell growth, and OptiPro supplemented with 2 μg/mL TPCK-trypsin (Sigma) was used for viral replication.12 (link) The harvested virus was inactivated with formaldehyde and then purified by clarification and chromatography.13 (link) This final bulk-produced H7N9 virus was considered the cell-derived PLS.